CINECA IRIS Institutional Research Information System

BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.527
SA - Sud America 686
EU - Europa 89
NA - Nord America 78
AF - Africa 30
OC - Oceania 1
Totale 2.411
Salva come PNG Salva come JPEG
Nazione #
BR - Brasile 540
HK - Hong Kong 473
SG - Singapore 325
VN - Vietnam 296
KR - Corea 198
CN - Cina 151
AR - Argentina 63
US - Stati Uniti d'America 62
EC - Ecuador 36
ID - Indonesia 31
IT - Italia 24
RU - Federazione Russa 20
FR - Francia 17
CO - Colombia 15
BD - Bangladesh 14
ZA - Sudafrica 14
MX - Messico 13
PY - Paraguay 12
CL - Cile 8
DE - Germania 8
GB - Regno Unito 8
IQ - Iraq 7
IN - India 6
UA - Ucraina 6
EG - Egitto 5
MA - Marocco 5
UZ - Uzbekistan 5
NP - Nepal 4
VE - Venezuela 4
IL - Israele 3
PK - Pakistan 3
UY - Uruguay 3
BO - Bolivia 2
IR - Iran 2
PE - Perù 2
TN - Tunisia 2
AU - Australia 1
BW - Botswana 1
BY - Bielorussia 1
CA - Canada 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
JP - Giappone 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
OM - Oman 1
PL - Polonia 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SE - Svezia 1
SN - Senegal 1
TR - Turchia 1
Totale 2.411
Salva come PNG Salva come JPEG
Città #
Hong Kong 473
Seoul 198
Singapore 147
Ho Chi Minh City 110
Hanoi 61
São Paulo 44
Sona 20
Haiphong 18
Beijing 17
Rio de Janeiro 16
Da Nang 14
Guayaquil 12
Ashburn 11
Dallas 11
Belo Horizonte 10
Mexico City 10
Quito 10
Biên Hòa 9
Manaus 9
Brasília 8
Curitiba 8
Porto Alegre 8
Buenos Aires 6
Campinas 6
Fortaleza 6
Goiânia 6
Hải Dương 6
Asunción 5
Boardman 5
Frankfurt am Main 5
Osasco 5
Phủ Lý 5
Piracicaba 5
Quảng Ngãi 5
Santo André 5
Sumaré 5
Tashkent 5
Bauru 4
Bogotá 4
Bragança Paulista 4
Can Tho 4
Franca 4
Guarulhos 4
Ha Long 4
Johannesburg 4
Joinville 4
Macaé 4
Ninh Bình 4
Recife 4
Salvador 4
São Gonçalo 4
Bandung 3
Belford Roxo 3
Cairo 3
Campina Grande 3
Cape Town 3
Caracas 3
Casablanca 3
Caxias do Sul 3
Chapecó 3
Criciúma 3
Dhaka 3
Florianópolis 3
Formosa 3
Hortolândia 3
Huế 3
Ibirité 3
Ipatinga 3
Itaquaquecetuba 3
Jakarta 3
Juiz de Fora 3
Los Angeles 3
Lấp Vò 3
Maceió 3
Marília 3
Mauá 3
Medellín 3
Montevideo 3
Phoenix 3
Quixadá 3
Quận Một 3
Ribeirão Preto 3
Rio Grande 3
Roubaix 3
Santos 3
Taboão da Serra 3
Thái Bình 3
Thái Nguyên 3
Uberlândia 3
Volta Redonda 3
Yên Bái 3
Anápolis 2
Baghdad 2
Belém 2
Blumenau 2
Bắc Giang 2
Cabreúva 2
Cachoeirinha 2
Campos dos Goytacazes 2
Cao Lanh 2
Totale 1.498
Salva come PNG Salva come JPEG
Nome #
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 48
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 46
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 46
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 44
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 44
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 41
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 40
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 39
AISF position paper on HCV in immunocompromised patients 39
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 36
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 35
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 34
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 33
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 33
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 33
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 31
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 31
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 30
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 30
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 30
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 30
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 30
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 30
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 29
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 29
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 29
Recent breakthroughs in the treatment of chronic hepatitis Delta 28
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 28
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 28
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 28
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 28
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 27
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 27
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 27
Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with Peg-Interferon and Ribavirin 27
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 27
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 27
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues 26
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 26
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 26
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 26
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 25
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 +  25
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 25
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 24
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 24
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 24
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 24
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 24
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 24
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 23
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 23
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 23
Hepatitis delta infection in Italian patients: towards the end of the story? 23
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 23
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 22
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 22
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 22
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 22
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 22
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 22
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 22
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 22
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 21
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 21
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 21
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 21
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 21
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 21
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 21
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 21
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 21
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 21
Hepatitis C Virus Clearance in Older Adults 21
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 20
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 20
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 20
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 19
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 19
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 19
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 19
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 19
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 18
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 18
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 18
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al 18
Virological patterns of HCV patients with failure to interferon-free regimens 18
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study 18
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 18
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 17
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 16
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 16
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 16
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 16
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 16
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 15
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 15
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 14
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 12
Association between sustained virological response and adverse liver-related events in patients with decompensated HCV cirrhosis 10
Totale 2.511
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025873 0 0 0 0 0 0 0 0 139 503 209 22
2025/20261.638 156 97 502 670 213 0 0 0 0 0 0 0
Totale 2.511